Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus GLYCORT.
DETROL LA vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category C
Category C
Anticholinergic
Anticholinergic